查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1857629

抗菌藥物敏感性測試市場（按產品類型、測試方法、方法論、應用和最終用戶分類）—全球預測，2025-2032年

Antimicrobial Susceptibility Testing Market by Product Type, Test Type, Method, Application, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗菌藥物敏感性測試市場規模將達到 64.3 億美元，複合年成長率為 6.02%。

關鍵市場統計數據
基準年 2024 40.2億美元
預計年份：2025年 42.5億美元
預測年份 2032 64.3億美元
複合年成長率 (%) 6.02%

一份簡潔的策略性介紹，概述了抗菌藥物敏感性檢測的趨勢、業務需求和診斷創新，旨在指導臨床和研發決策。

抗菌藥物敏感性試驗是臨床微生物學和治療管理的基礎，對全球的治療決策、監測活動和藥物開發平臺都產生深遠的影響。本執行摘要總結了當前該領域的主要趨勢、技術曲折點、監管壓力和商業需求。本書旨在為實驗室、醫療保健系統、藥物研發和公共衛生領域的領導者提供簡潔扼要、基於實證的簡報，幫助他們更好地應對不斷變化的臨床和商業性需求。

自動化、分子診斷、勞動力限制和整合服務如何重塑實驗室工作流程和診斷供應商關係

近年來，診斷技術、實驗室操作以及支持抗菌藥物管理的整個生態系統都發生了變革性變化。自動化程度正從獨立的分析儀發展到完全整合的平台，這些平台整合了自動化系統、盤式分析儀和資料處理流程。這項變更不僅縮短了周轉時間，還提高了可重複性和資料完整性，使大型中心能夠在保證品質的前提下擴大偵測能力。同時，基因型鑒定方法和分子檢測技術的進步提供了與傳統表現型檢測互補的資訊，加速了抗藥性決定因素的識別，並為精準醫療提供了資訊。

在不斷變化的關稅環境下，評估貿易政策對診斷採購、試劑持續供應和資本採購選擇的累積影響

政策變化，例如關稅和跨境貿易成本的調整，會對診斷供應鏈和籌資策略產生連鎖反應，進而影響設備採購、試劑供應和價格動態。當進口診斷組件或成品設備的關稅提高時，實驗室和製造商將面臨更高的到岸成本，這往往迫使他們重新評估供應商合約和庫存策略。有些機構會加速在地採購，尋找合適的供應商；而有些機構則會協商長期供應協議，以避免貿易波動帶來的風險。此外，關稅上漲還可能影響資本投資決策的時機，促使買家延長設備使用壽命或優先考慮模組化升級而非整體更換。

細分分析整合了產品、測試、方法、應用和最終用戶觀點，以確定創新和商業化的優先目標。

了解產品、測試、方法、應用和最終用戶等細分領域之間的交集，對於協調研發重點、籌資策略和商業化計劃至關重要。產品類型涵蓋儀器、試劑盒和服務。儀器包括自動化系統和手動系統，可進一步細分為自動化分析儀和自動盤式分析儀。試劑盒分為抗生素敏感性測試試劑盒和微生物鑑定試劑盒，而服務則涵蓋分析測試服務和客製化測試解決方案。這種產品層面的細分凸顯了自動化投資與試劑組合或外包服務投資的不同之處，前者對耗材消耗、供應商鎖定和工作流程重組的影響也截然不同。

診斷簡介及美洲、歐洲、中東和非洲以及亞太地區的供應鏈策略

區域動態正在塑造需求模式和供應鏈策略，因此，對全球規劃而言，細緻的跨區域視角至關重要。在美洲，大型醫院網路、先進的臨床實驗室以及對抗菌藥物管理的重視，加上支付方和監管機構的期望，共同推動了自動化和互聯診斷平台的普及應用。確保試劑和耗材的穩定供應需要本地化的庫存策略和長期的供應商關係。在歐洲、中東和非洲，監管環境的差異和資源的多樣性導致了不同的應用路徑。一些歐洲市場的領先實驗室優先發展先進的分子診斷和自動化表現型分析工作流程，而該地區的其他一些市場則更注重成本效益高、穩健可靠且基礎設施有限的大規模部署方法。

儀器供應商、試劑專家和服務供應商之間的競爭動態和合作策略正在塑造平台整合和經常性收入模式。

競爭格局由成熟的診斷設備製造商、專業試劑製造商以及提供分析測試和客製化解決方案的服務供應商組成。現有設備供應商持續投資於平台整合、軟體驅動的決策支援和互通性，以保持其在臨床實驗室的競爭力。同時，規模較小、更靈活的公司正在推進基因型檢測和針對特定抗藥性機制的專用試劑組，從而為尋求擴展檢測專案的大型公司創造合作機會。服務供應商透過提供端到端的驗證支援、遠端設備監控以及旨在滿足監管申報要求的客製化檢測方案來脫穎而出。

為高階主管提供可操作的建議，以增強韌性、加快自動化採用，並建立滿足用戶需求的差異化產品和服務。

領導者必須採取審慎行動，抓住機遇，規避風險。首先，應優先投資自動化和互通軟體，以減少人工操作，提高可重複性，並實現臨床和研究環境中的可擴展測試。其次，應實現供應鏈多元化，對關鍵試劑和耗材的替代供應商進行資格認證，並建立合約機制，以便在供應中斷時能夠靈活承諾數量並優先履行義務。此外，還應加強診斷開發人員和最終用戶之間的合​​作，共同設計檢驗測試和服務模式，以應對實際實驗室的限制和監管要求。

結合一手訪談、技術檢驗和二手證據的穩健混合調查方法，確保了研究的實用性和方法論的嚴謹性。

調查方法，結合了初步訪談、嚴謹的二次驗證與技術檢驗。初步數據透過實驗室主任、採購主管、診斷試劑研發人員和服務供應商的結構化訪談收集，以了解他們的業務重點、採購促進因素和創新藍圖。二次研究整合了同行評審文獻、監管指南和技術白皮書，以檢驗定性檢測方法和定量檢測方法之間的差異，並了解自動化分析儀、自動盤式分析儀和分子檢測方法的性能標準演變。

總結觀點，應協調技術、營運和商業性策略，以實現先進藥敏試驗的臨床和公共衛生效益。

抗菌藥物敏感性檢測正處於曲折點，技術創新、營運壓力和政策動態正在交匯融合，重塑診斷實踐。持續推進自動化、互補基因分型方法和數據驅動的管理工具，可望加速診斷並改善臨床決策，同時也對驗證、互通性和從業人員能力提出了新的要求。供應鏈的韌性和靈活的商業模式將影響實驗室和研究機構採用新平台和檢測方法的速度。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 採用快速微流體抗生素敏感性試驗系統，實現同班次抗生素最佳化
  • 將人工智慧主導的影像分析整合到AST平台中，以提高結果準確性
  • 擴展基於次世代定序的藥敏試驗，以實現全面的抗藥性分析
  • 自動擴散試驗閱片器的出現降低了人工判讀結果的差異性。
  • 針對多重抗藥性病原體檢測的多重藥敏試驗板的需求日益成長
  • 加速核准基於微孔盤的藥敏試驗試劑盒，以滿足迫切的臨床需求
  • 診斷公司與人工智慧新興企業建立策略夥伴關係，共同開發AST分析技術
  • 實施雲端基礎的AST數據管理系統，用於即時監測報告

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按產品類型分類的抗菌藥物敏感性測試市場

  • 裝置
    • 自動化系統
      • 自動分析儀
      • 自動盤式分析儀
    • 手動裝置
  • 試劑和試劑盒
    • 抗生素敏感性檢測試劑盒
    • 微生物鑑定試劑盒
  • 服務
    • 分析測試服務
    • 客製化檢驗解決方案

9. 依檢測方法分類的抗菌藥物敏感性檢測市場

  • 抗菌藥物敏感性試驗
  • 抗真菌藥物敏感性試驗
  • 抗寄生蟲藥物敏感性試驗
  • 抗病毒藥物敏感性試驗

第10章 依方法論分類的抗菌藥物敏感性測試市場

  • 定性方法
    • 瓊脂稀釋法
    • 自動化藥物敏感性檢測方法
    • 紙錠擴散法
    • 基因分型方法
  • 定量方法
    • 肉湯大稀釋法
    • Etest 方法

第11章 按應用分類的抗菌藥物敏感性測試市場

  • 臨床診斷
  • 藥物研發
  • 流行病學

第12章：按最終用戶分類的抗菌藥物敏感性測試市場

  • 學術和政府研究機構
  • 醫院和診斷中心
  • 製藥和生物技術公司

13. 按地區分類的抗菌藥物敏感性檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 抗菌藥物敏感性測試市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國抗菌藥物敏感性檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Accelerate Diagnostics, Inc.
    • Alifax Srl
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • BIOANALYSE TIbbi Malz. San. ve Tic. Ltd. Sti.
    • Biological Safety Solutions Ltd/Oy
    • BioMerieux SA
    • Bruker Corporation
    • Creative Diagnostics
    • Danaher Corporation
    • Erba Lachema sro
    • Eurofins Scientific SE
    • F. Hoffmann-La Roche AG
    • Himedia Laboratories Private Limited
    • INTEGRA Biosciences AG
    • Laboratorios Conda, SA
    • Launch Diagnostics Limited
    • Leading Biology, Inc.
    • Liofilchem Srl
    • Mast Group Ltd.
    • MP Biomedicals, LLC
    • Pfizer Inc.
    • Qiagen NV
    • QuantaMatrix Inc.
    • Resistell AG
    • Synoptics Group
    • Thermo Fisher Scientific Inc.
    • Zhuhai DL Biotech Co., Ltd.
Product Code: MRR-464C422F4BD3

The Antimicrobial Susceptibility Testing Market is projected to grow by USD 6.43 billion at a CAGR of 6.02% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.02 billion
Estimated Year [2025] USD 4.25 billion
Forecast Year [2032] USD 6.43 billion
CAGR (%) 6.02%

A concise strategic introduction framing antimicrobial susceptibility testing trends, operational imperatives, and diagnostic innovation that guide clinical and R&D decision-making

Antimicrobial susceptibility testing is a cornerstone of clinical microbiology and therapeutic stewardship, influencing treatment decisions, surveillance activities, and drug development pipelines worldwide. This executive summary synthesizes cross-cutting trends, technological inflection points, regulatory pressures, and operational imperatives shaping the field today. It aims to provide a concise, evidence-based briefing for leaders in laboratories, health systems, pharmaceutical development, and public health who must align capabilities with evolving clinical and commercial demands.

The landscape is defined by the convergence of automation, molecular diagnostics, and data-driven decision support. Faster time-to-result and improved reproducibility are driving investment in automated instruments and integrated workflows, while genotypic approaches complement phenotypic assays to give clinicians a richer understanding of resistance mechanisms. At the same time, regulatory scrutiny of diagnostic performance, reimbursement dynamics, and supply chain resiliency continue to affect implementation timelines and capital allocation. This introduction frames the topics addressed in the following sections and sets expectations for actionable insights that follow, positioning readers to evaluate strategic options in procurement, laboratory modernization, and collaborative research.

How automation, molecular diagnostics, workforce constraints, and integrated services are reshaping laboratory workflows and supplier relationships in diagnostics

Recent years have ushered in transformative shifts across diagnostic technology, laboratory operations, and the broader ecosystem that supports antimicrobial stewardship. Automation has moved beyond stand-alone analyzers toward fully integrated platforms that combine automated systems, plate readers, and connected data pipelines. This change not only reduces hands-on time but also elevates reproducibility and data integrity, enabling larger institutions to scale testing capacity while maintaining quality. Simultaneously, advances in genotypic methods and molecular panels are providing complementary insights to traditional phenotypic assays, accelerating identification of resistance determinants and informing precision therapy.

Workforce dynamics and laboratory consolidation are forcing organizations to rethink workflows; shortages of skilled technicians increase the value of automation and remote monitoring capabilities. Reagents and kits are evolving too, with manufacturers optimizing formulations for stability and compatibility with automated analyzers and automated plate readers to reduce variability and logistical burden. Services are expanding beyond routine analytical testing to offer custom testing solutions and advisory support for assay validation and regulatory submissions. Taken together, these forces are reshaping procurement priorities, vendor relationships, and the structure of diagnostic service offerings, prompting stakeholders to prioritize agile, interoperable solutions that support both clinical diagnostics and drug development pathways.

Evaluating cumulative trade policy impacts on diagnostic sourcing, reagent continuity, and capital procurement choices amid changing tariff environments

Policy shifts that alter duties and cross-border trade costs can ripple through diagnostic supply chains and procurement strategies, influencing instrument sourcing, reagent availability, and pricing dynamics. When tariffs increase on imported diagnostic components or finished instruments, laboratories and manufacturers face higher landed costs that often require re-evaluation of supplier contracts and inventory strategies. Some organizations respond by accelerating local sourcing where capable suppliers exist, while others negotiate long-term supply agreements to hedge exposure to trade volatility. In addition, higher tariffs can affect the cadence of capital investment decisions, prompting buyers to extend equipment lifecycles or prioritize modular upgrades over full platform replacements.

Beyond direct cost effects, tariff changes can create secondary impacts on innovation diffusion and service delivery. Manufacturers with geographically diversified production footprints may reallocate manufacturing to regions with preferential trade terms, which can alter lead times and qualification requirements for regulatory filings. Service providers that perform analytical testing and custom testing solutions may need to adjust pricing or revise cross-border service agreements to maintain margins. For clinical entities and research organizations, the pragmatic response often combines inventory buffering, supplier diversification, and closer collaboration with vendors to secure continuity of reagents and critical consumables. Ultimately, the cumulative effects of tariff shifts emphasize the importance of resilient sourcing strategies, contractual flexibility, and scenario planning to manage supply chain risk while sustaining diagnostic quality and operational continuity.

Integrated segmentation analysis that aligns product, test, method, application, and end-user perspectives to reveal priority targets for innovation and commercialization

Understanding how product, test, method, application, and end-user segments intersect is essential to aligning R&D priorities, procurement strategies, and commercialization plans. Based on product type, the landscape spans instruments, reagents and kits, and services; instruments include automated systems and manual instruments, with automated systems further differentiated into automated analyzers and automated plate readers; reagents and kits divide into antibiotic susceptibility kits and microbial identification kits; and services encompass analytical testing services and custom testing solutions. This product-level distinction underscores that investments in automation will carry different implications for consumable consumption, vendor lock-in, and workflow redesign than investments in reagent portfolios or outsourced services.

Test type segmentation reflects clinical and research needs across antibacterial susceptibility testing, antifungal susceptibility testing, antiparasitic susceptibility testing, and antiviral susceptibility testing, each with distinct methodological requirements and clinical urgency. Method segmentation separates qualitative and quantitative approaches; qualitative methods include agar dilution, automated AST, disk diffusion, and genotypic methods, while quantitative methods comprise broth macrodilution and the Etest method. These methodological differences influence laboratory throughput, interpretive complexity, and regulatory validation pathways. Application segmentation shows demand centers in clinical diagnostics, drug discovery and development, and epidemiology, which in turn shape acceptance criteria and data deliverables. Finally, end-user segmentation identifies academic and government research institutes, hospitals and diagnostic centers, and pharmaceutical and biotechnology companies as primary consumers, each with unique procurement cycles, performance expectations, and budgetary constraints. Combining these lenses reveals where innovation will be most valuable, which channels require targeted commercial strategies, and how validation and service models should be configured to meet user needs.

Regional diagnostic adoption and supply chain strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific that inform tailored commercial approaches

Regional dynamics shape both demand patterns and supply chain strategies, and a nuanced view across geographies is critical for global planning. In the Americas, demand is driven by large hospital networks, advanced clinical laboratories, and a strong emphasis on antimicrobial stewardship tied to payer and regulatory expectations, which favors adoption of automation and connected diagnostic platforms. Supply chain resilience is a recurring concern, motivating local inventory strategies and longer-term supplier relationships to ensure steady access to reagents and consumables. Across Europe, Middle East & Africa, regulatory heterogeneity and resource variability create differentiated adoption trajectories; leading laboratories in some European markets prioritize advanced molecular and automated phenotypic workflows, while parts of the broader region focus on cost-effective, robust methods that can be deployed at scale with constrained infrastructure.

Asia-Pacific presents a mixed picture of rapid capacity expansion, significant public health-driven surveillance programs, and growing domestic manufacturing capabilities for reagents and instruments. Investment in laboratory infrastructure and public health surveillance is increasing in many markets, bolstering demand for both automated systems and analytical testing services. These regional contrasts mean that product design, commercial models, and partnership strategies must be tailored; solutions that succeed in one geography may need adaptation in pricing, service delivery, and regulatory support to achieve traction elsewhere. Cross-border collaboration and strategic regional partnerships can help bridge capability gaps, accelerate technology transfer, and align supply networks with regional priorities.

Competitive dynamics and partnership strategies among instrument vendors, reagent specialists, and service providers shaping platform integration and recurring revenue models

The competitive landscape is being shaped by a mix of established diagnostic manufacturers, specialized reagent suppliers, and service providers offering analytical testing and custom solutions. Incumbent instrument vendors continue to invest in platform integration, software-enabled decision support, and interoperability to maintain clinical laboratory relevance. At the same time, smaller and more agile firms are advancing genotypic assays and niche reagent kits that address specific resistance mechanisms, enabling partnership opportunities with larger firms seeking to broaden their test menus. Service providers are differentiating by offering end-to-end validation support, remote instrument monitoring, and customized testing panels designed to meet regulatory submission needs.

Strategic behavior includes forming alliances to accelerate market entry, pursuing acquisitions to fill portfolio gaps, and expanding service capabilities to capture recurring revenue from consumables and testing contracts. Manufacturers are also investing in digital tools that aggregate susceptibility data for local surveillance and stewardship programs, creating stickiness and value beyond the instrument sale. For pharmaceutical and biotechnology companies, collaborations with diagnostic developers and contract service providers are increasingly important to de-risk antimicrobial drug development through integrated testing strategies. Overall, competitive advantage accrues to organizations that combine technical excellence with adaptable commercial models, robust supply chains, and strong customer support frameworks.

Actionable recommendations for executives to strengthen resilience, accelerate automation adoption, and build differentiated product and service offerings aligned with user needs

Leaders must act deliberately to capture opportunities and mitigate risk. First, prioritize investments in automation and interoperable software that reduce manual workload, improve reproducibility, and enable scalable testing across clinical and research settings. Next, diversify supply chains and qualify alternate suppliers for key reagents and consumables, and establish contractual mechanisms that allow flexible volume commitments and priority fulfillment during supply disruptions. Strengthen collaboration between diagnostic developers and end users by co-designing validation studies and service models that address real-world laboratory constraints and regulatory expectations.

Additionally, invest in workforce development to close skill gaps through targeted training programs, remote monitoring tools, and workflow redesign that optimize the use of scarce specialist talent. For companies commercializing tests or instruments, adopt flexible pricing and service bundles that reflect the needs of distinct end users such as academic research centers, hospital systems, and pharmaceutical development teams. Finally, integrate surveillance data products and stewardship support into offerings to create differentiated value, foster long-term customer relationships, and demonstrate public health impact. These steps create a pragmatic roadmap to balance short-term resilience with long-term growth and innovation.

Robust mixed-methods research approach combining primary interviews, technical validation, and secondary evidence to ensure practical relevance and methodological rigor

The research approach combines a layered methodology that integrates primary interviews, rigorous secondary source triangulation, and technical validation exercises. Primary data was collected through structured interviews with laboratory directors, procurement leads, diagnostic developers, and service providers to capture operational priorities, procurement drivers, and innovation roadmaps. Secondary research synthesized peer-reviewed literature, regulatory guidance, and technical white papers to validate methodological distinctions across qualitative and quantitative testing approaches and to understand evolving performance standards for automated analyzers, automated plate readers, and molecular assays.

Technical validation involved cross-referencing method characteristics-such as throughput, time-to-result, and interpretive complexity-against documented laboratory workflows and published performance evaluations for genotypic and phenotypic methods. Supply chain and policy analyses incorporated trade data and public procurement patterns to assess vulnerability points and potential mitigation strategies. Throughout, findings were iteratively reviewed with subject matter experts to ensure accuracy and practical relevance. This mixed-methods design ensures that conclusions are grounded in real-world practice while reflecting the technical nuances of assay development, instrument integration, and service delivery.

Concluding perspective on aligning technological, operational, and commercial strategies to realize the clinical and public health benefits of advanced susceptibility testing

Antimicrobial susceptibility testing is at an inflection point where technological innovation, operational pressures, and policy dynamics converge to reshape diagnostic practice. The continued push toward automation, complementary genotypic methods, and data-enabled stewardship tools promises to improve diagnostic speed and clinical decision-making, while also introducing new requirements for validation, interoperability, and workforce competencies. Supply chain resilience and adaptable commercial models will influence how quickly laboratories and research organizations can adopt new platforms and assays.

Stakeholders that align investment with clear use-case prioritization-distinguishing the needs of clinical diagnostics, drug discovery and development, and epidemiology-will capture the greatest value. By integrating product-level strategies, regional tailoring, and partnerships that bridge technical and commercial gaps, organizations can both mitigate near-term risks and position themselves for sustained impact. The path forward favors pragmatic innovation that is interoperable, validated in real-world settings, and supported by service models that address the full lifecycle of instruments, reagents, and testing programs.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of rapid microfluidic AST systems enabling same shift antibiotic optimization
  • 5.2. Integration of AI-driven image analysis in AST platforms for enhanced result accuracy
  • 5.3. Expansion of next-generation sequencing-based AST assays for comprehensive resistance profiling
  • 5.4. Emergence of automated disc diffusion readers reducing manual interpretation variability
  • 5.5. Growing demand for multiplexed AST panels targeting multidrug-resistant pathogen detection
  • 5.6. Regulatory approval acceleration for microplate-based AST kits to meet urgent clinical needs
  • 5.7. Strategic partnerships between diagnostic firms and AI startups to co-develop AST analytics
  • 5.8. Implementation of cloud-based AST data management systems for real-time surveillance reporting

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antimicrobial Susceptibility Testing Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Automated Systems
      • 8.1.1.1. Automated Analyzers
      • 8.1.1.2. Automated Plate Readers
    • 8.1.2. Manual Instruments
  • 8.2. Reagents & Kits
    • 8.2.1. Antibiotic Susceptibility Kits
    • 8.2.2. Microbial Identification Kits
  • 8.3. Services
    • 8.3.1. Analytical Testing Services
    • 8.3.2. Custom Testing Solutions

9. Antimicrobial Susceptibility Testing Market, by Test Type

  • 9.1. Antibacterial Susceptibility Testing
  • 9.2. Antifungal Susceptibility Testing
  • 9.3. Antiparasitic Susceptibility Testing
  • 9.4. Antiviral Susceptibility Testing

10. Antimicrobial Susceptibility Testing Market, by Method

  • 10.1. Qualitative Methods
    • 10.1.1. Agar Dilution
    • 10.1.2. Automated Ast
    • 10.1.3. Disk Diffusion
    • 10.1.4. Genotypic Method
  • 10.2. Quantitative Methods
    • 10.2.1. Broth Macrodilution
    • 10.2.2. Etest Method

11. Antimicrobial Susceptibility Testing Market, by Application

  • 11.1. Clinical Diagnostics
  • 11.2. Drug Discovery & Development
  • 11.3. Epidemiology

12. Antimicrobial Susceptibility Testing Market, by End User

  • 12.1. Academic & Government Research Institutes
  • 12.2. Hospitals & Diagnostic Centers
  • 12.3. Pharmaceutical & Biotechnology Companies

13. Antimicrobial Susceptibility Testing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Antimicrobial Susceptibility Testing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Antimicrobial Susceptibility Testing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Accelerate Diagnostics, Inc.
    • 16.3.2. Alifax S.r.l.
    • 16.3.3. Becton, Dickinson and Company
    • 16.3.4. Bio-Rad Laboratories, Inc.
    • 16.3.5. BIOANALYSE TIbbi Malz. San. ve Tic. Ltd. Sti.
    • 16.3.6. Biological Safety Solutions Ltd/Oy
    • 16.3.7. BioMerieux SA
    • 16.3.8. Bruker Corporation
    • 16.3.9. Creative Diagnostics
    • 16.3.10. Danaher Corporation
    • 16.3.11. Erba Lachema s.r.o.
    • 16.3.12. Eurofins Scientific SE
    • 16.3.13. F. Hoffmann-La Roche AG
    • 16.3.14. Himedia Laboratories Private Limited
    • 16.3.15. INTEGRA Biosciences AG
    • 16.3.16. Laboratorios Conda, S.A.
    • 16.3.17. Launch Diagnostics Limited
    • 16.3.18. Leading Biology, Inc.
    • 16.3.19. Liofilchem S.r.l.
    • 16.3.20. Mast Group Ltd.
    • 16.3.21. MP Biomedicals, LLC
    • 16.3.22. Pfizer Inc.
    • 16.3.23. Qiagen N.V.
    • 16.3.24. QuantaMatrix Inc.
    • 16.3.25. Resistell AG
    • 16.3.26. Synoptics Group
    • 16.3.27. Thermo Fisher Scientific Inc.
    • 16.3.28. Zhuhai DL Biotech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED PLATE READERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED PLATE READERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED PLATE READERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED PLATE READERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED PLATE READERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED PLATE READERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBIOTIC SUSCEPTIBILITY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBIOTIC SUSCEPTIBILITY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBIOTIC SUSCEPTIBILITY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBIOTIC SUSCEPTIBILITY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBIOTIC SUSCEPTIBILITY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBIOTIC SUSCEPTIBILITY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROBIAL IDENTIFICATION KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROBIAL IDENTIFICATION KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROBIAL IDENTIFICATION KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROBIAL IDENTIFICATION KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROBIAL IDENTIFICATION KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROBIAL IDENTIFICATION KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CUSTOM TESTING SOLUTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CUSTOM TESTING SOLUTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CUSTOM TESTING SOLUTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CUSTOM TESTING SOLUTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CUSTOM TESTING SOLUTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CUSTOM TESTING SOLUTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIVIRAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIVIRAL SUSCEPTIBILITY TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIVIRAL SUSCEPTIBILITY TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIVIRAL SUSCEPTIBILITY TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIVIRAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIVIRAL SUSCEPTIBILITY TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED AST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED AST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED AST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED AST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED AST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED AST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPIC METHOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPIC METHOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPIC METHOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPIC METHOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPIC METHOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPIC METHOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MACRODILUTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MACRODILUTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MACRODILUTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MACRODILUTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MACRODILUTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MACRODILUTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 211. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 212. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 233. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 234. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 256. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA ANTIMICROBIAL SUSCEPTI